Search Results - "Abbruzzese, James L"

Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer by Andersen, Dana K, Korc, Murray, Petersen, Gloria M, Eibl, Guido, Li, Donghui, Rickels, Michael R, Chari, Suresh T, Abbruzzese, James L

“…The relationships between diabetes and pancreatic ductal adenocarcinoma (PDAC) are complex. Longstanding type 2 diabetes (T2DM) is a risk factor for pancreatic…”
Get full text

Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed? by OVERMAN, Michael J, MODAK, Janhavi, KOPETZ, Scott, MURTHY, Ravi, YAO, James C, HICKS, Marshall E, ABBRUZZESE, James L, TAM, Alda L

“…Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed…”
Get full text

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer by ARUMUGAM, Thiruvengadam, RAMACHANDRAN, Vijaya, FOURNIER, Keith F, HUAMIN WANG, MARQUIS, Lauren, ABBRUZZESE, James L, GALLICK, Gary E, LOGSDON, Craig D, MCCONKEY, David J, CHOI, Woonyoung

“…A better understanding of drug resistance mechanisms is required to improve outcomes in patients with pancreatic cancer. Here, we characterized patterns of…”
Get full text

Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer by Dhillon, Navneet, Aggarwal, Bharat B, Newman, Robert A, Wolff, Robert A, Kunnumakkara, Ajaikumar B, Abbruzzese, James L, Ng, Chaan S, Badmaev, Vladimir, Kurzrock, Razelle

“…Purpose: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration–approved therapies for it, gemcitabine and erlotinib,…”
Get full text

Antidiabetic Therapies Affect Risk of Pancreatic Cancer by Li, Donghui, Yeung, Sai–Ching J, Hassan, Manal M, Konopleva, Marina, Abbruzzese, James L

“…Background & Aims Antidiabetic drugs have been found to have various effects on cancer in experimental systems and in epidemiologic studies, although the…”
Get full text

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma by Kim, Michael P, Fleming, Jason B, Wang, Huamin, Abbruzzese, James L, Choi, Woonyoung, Kopetz, Scott, McConkey, David J, Evans, Douglas B, Gallick, Gary E

“…Multiple studies in recent years have identified highly tumorigenic populations of cells that drive tumor formation. These cancer stem cells (CSCs), or…”
Get full text

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer by Capello, Michela, Bantis, Leonidas E, Scelo, Ghislaine, Zhao, Yang, Li, Peng, Dhillon, Dilsher S, Patel, Nikul J, Kundnani, Deepali L, Wang, Hong, Abbruzzese, James L, Maitra, Anirban, Tempero, Margaret A, Brand, Randall, Firpo, Matthew A, Mulvihill, Sean J, Katz, Matthew H, Brennan, Paul, Feng, Ziding, Taguchi, Ayumu, Hanash, Samir M

“…CA19-9, which is currently in clinical use as a pancreatic ductal adenocarcinoma (PDAC) biomarker, has limited performance in detecting early-stage disease. We…”
Get full text

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205 by PHILIP, Philip A, BENEDETTI, Jacqueline, KHORANA, Alok A, GOLDMAN, Bryan, FENOGLIO-PREISER, Cecilia M, ABBRUZZESE, James L, BLANKE, Charles D, CORLESS, Christopher L, WONG, Ralph, O'REILLY, Eileen M, FLYNN, Patrick J, ROWLAND, Kendrith M, ATKINS, James N, MIRTSCHING, Barry C, RIVKIN, Saul E

“…Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has…”
Get full text

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance by KOPETZ, Scott, HOFF, Paulo M, LIEU, Christopher, SHAOYU YAN, TRAN, Hai T, ELLIS, Lee M, ABBRUZZESE, James L, HEYMACH, John V, MORRIS, Jeffrey S, WOLFF, Robert A, ENG, Cathy, GLOVER, Katrina Y, ADININ, Rosie, OVERMAN, Michael J, VALERO, Vincete, SIJIN WEN

“…We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated…”
Get full text

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression by CRANE, Christopher H, VARADHACHARY, Gauri R, DAS, Prajnan, LEE, Jeffrey E, ABBRUZZESE, James L, WOLFF, Robert A, YORDY, John S, STAERKEL, Gregg A, JAVLE, Milind M, SAFRAN, Howard, HAQUE, Waqar, HOBBS, Bridgett D, KRISHNAN, Sunil, FLEMING, Jason B

“…This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and…”
Get full text

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice by Gallick, Gary E, Kim, Michael P, Evans, Douglas B, Wang, Huamin, Abbruzzese, James L, Fleming, Jason B

“…For decades, xenografts using well-established human tumor cell lines have been the most commonly used models to study human cancers in mice. More recently,…”
Get full text

Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet by Luo, Yongde, Yang, Yaying, Liu, Muyun, Wang, Dan, Wang, Feng, Bi, Yawei, Ji, Juntao, Li, Suyun, Liu, Yan, Chen, Rong, Huang, Haojie, Wang, Xiaojie, Swidnicka-Siergiejko, Agnieszka K., Janowitz, Tobias, Beyaz, Semir, Wang, Guoqiang, Xu, Sulan, Bialkowska, Agnieszka B., Luo, Catherine K., Pin, Christoph L., Liang, Guang, Lu, Xiongbin, Wu, Maoxin, Shroyer, Kenneth R., Wolff, Robert A., Plunkett, William, Ji, Baoan, Li, Zhaoshen, Li, Ellen, Li, Xiaokun, Yang, Vincent W., Logsdon, Craig D., Abbruzzese, James L., Lu, Weiqin

“…Obesity is a risk factor for pancreatic cancer. In mice, a high-fat diet (HFD) and expression of oncogenic KRAS lead to development of invasive pancreatic…”
Get full text

New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts by DONGHUI LI, ABBRUZZESE, James L

“…Pancreatic cancer (PC) is a highly lethal disease with complex etiology involving both environmental and genetic factors. Although cigarette smoking is known…”
Get full text

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b by YAO, James C, PHAN, Alexandria, HOFF, Paulo M, CHEN, Helen X, CHARNSANGAVEJ, Chusilp, YEUNG, Sai-Ching J, HESS, Kenneth, NG, Chaan, ABBRUZZESE, James L, AJANI, Jaffer A

“…Purpose Effective systemic therapy for advanced carcinoid is lacking. The combination of bevacizumab (BEV) and pegylated (PEG) interferon alfa-2b was evaluated…”
Get full text

Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1 by Melisi, Davide, Xia, Qianghua, Paradiso, Genni, Ling, Jianhua, Moccia, Tania, Carbone, Carmine, Budillon, Alfredo, Abbruzzese, James L., Chiao, Paul J.

“…Background TGF-β-activated kinase-1 (TAK1), a mitogen-activated protein kinase kinase kinase, functions in the activation of nuclear factor κB (NF-κB) and…”
Get full text

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head by EVANS, Douglas B, VARADHACHARY, Gauri R, CHARNSANGAVEJ, Chusilp, LANO, Elizabeth A, HO, Linus, LENZI, Renato, ABBRUZZESE, James L, WOLFF, Robert A, CRANE, Christopher H, SUN, Charlotte C, LEE, Jeffrey E, PISTERS, Peter W. T, VAUTHEY, Jean-Nicolas, HUAMIN WANG, CLEARY, Karen R, STAERKEL, Gregg A

“…We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD)…”
Get full text

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience by Cloyd, Jordan M., Katz, Matthew H. G., Prakash, Laura, Varadhachary, Gauri R., Wolff, Robert A., Shroff, Rachna T., Javle, Milind, Fogelman, David, Overman, Michael, Crane, Christopher H., Koay, Eugene J., Das, Prajnan, Krishnan, Sunil, Minsky, Bruce D., Lee, Jeffrey H., Bhutani, Manoop S., Weston, Brian, Ross, William, Bhosale, Priya, Tamm, Eric P., Wang, Huamin, Maitra, Anirban, Kim, Michael P., Aloia, Thomas A., Vauthey, Jean-Nicholas, Fleming, Jason B., Abbruzzese, James L., Pisters, Peter W. T., Evans, Douglas B., Lee, Jeffrey E.

“…Background The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal…”
Get full text

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma by RATAIN, Mark J, EISEN, Tim, ROWINSKY, Eric, ABBRUZZESE, James L, CHENGHUA XIA, SIMANTOV, Ronit, SCHWARTZ, Brian, O'DWYER, Peter J, STADLER, Walter M, FLAHERTY, Keith T, KAYE, Stan B, ROSNER, Gary L, GORE, Martin, DESAI, Apurva A, PATNAIK, Amita, XIONG, Henry Q

“…This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and…”
Get full text

Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival by Tzeng, Ching-Wei D., Cao, Hop S. Tran, Lee, Jeffrey E., Pisters, Peter W. T., Varadhachary, Gauri R., Wolff, Robert A., Abbruzzese, James L., Crane, Christopher H., Evans, Douglas B., Wang, Huamin, Abbott, Daniel E., Vauthey, Jean-Nicolas, Aloia, Thomas A., Fleming, Jason B., Katz, Matthew H. G.

“…Barriers to multimodality therapy (MMT) completion among patients with resectable pancreatic adenocarcinoma include early cancer progression and postoperative…”
Get full text

Metastatic patterns in adenocarcinoma by Hess, Kenneth R., Varadhachary, Gauri R., Taylor, Sarah H., Wei, Wei, Raber, Martin N., Lenzi, Renato, Abbruzzese, James L.

“…BACKGROUND Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports. The authors analyzed…”
Get full text